Back

Atypical Cell Cycle Regulation Promotes Mammary Stem Cell Expansion and Therapeutic Resistance

Fifield, B.-A.; Vusich, J.; Haberfellner, E.; Andrechek, E. R.; Porter, L. A.

2024-03-08 cancer biology
10.1101/2024.03.05.583524 bioRxiv
Show abstract

BackgroundThe cell cycle of mammary stem cells must be tightly regulated to ensure normal homeostasis of the mammary gland to prevent abnormal proliferation and susceptibility to tumorigenesis. The atypical cell cycle regulator, Spy1 can override cell cycle checkpoints, including those activated by the tumour suppressor p53 which mediates mammary stem cell homeostasis. Spy1 has also been shown to promote expansion of select stem cell populations in other developmental systems. Spy1 protein is elevated during proliferative stages of mammary gland development, is found at higher levels in human breast cancers, and promotes susceptibility to mammary tumourigenesis when combined with loss of p53. We hypothesized that Spy1 cooperates with loss of p53 to increase susceptibility to tumour initiation due to changes in susceptible mammary stem cell populations during development and drives the formation of more aggressive stem like tumours. MethodsUsing a transgenic mouse model driving expression of Spy1 within the mammary gland, mammary development and stemness were assessed. These mice were intercrossed with p53 null mice to study the tumourigenic properties of Spy1 driven p53 null tumours, as well as global changes in signaling via RNA sequencing analysis. ResultsWe show that elevated levels of Spy1 leads to expansion of mammary stem cells, even in the presence of p53, and an increase in mammary tumour formation. Spy1-driven tumours have an increased cancer stem cell population, decreased checkpoint signaling, and demonstrate an increase in therapy resistance. Loss of Spy1 decreases tumor onset and reduces the cancer stem cell population. ConclusionsThis data demonstrates the potential of Spy1 to expand mammary stem cell populations and contribute to the initiation and progression of aggressive, drug resistant breast cancers with increased cancer stem cell populations.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Breast Cancer Research
32 papers in training set
Top 0.1%
29.4%
2
Cancers
200 papers in training set
Top 0.3%
10.7%
3
PLOS ONE
4510 papers in training set
Top 21%
8.7%
4
Scientific Reports
3102 papers in training set
Top 32%
3.9%
50% of probability mass above
5
International Journal of Cancer
42 papers in training set
Top 0.4%
2.5%
6
BMC Cancer
52 papers in training set
Top 1%
2.0%
7
JNCI Cancer Spectrum
10 papers in training set
Top 0.2%
1.9%
8
Disease Models & Mechanisms
119 papers in training set
Top 0.9%
1.9%
9
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.3%
1.8%
10
F1000Research
79 papers in training set
Top 1%
1.8%
11
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 5%
1.6%
12
Cancer Research
116 papers in training set
Top 2%
1.6%
13
BMC Genomics
328 papers in training set
Top 3%
1.4%
14
Cell Reports Medicine
140 papers in training set
Top 5%
1.3%
15
npj Breast Cancer
18 papers in training set
Top 0.1%
1.3%
16
npj Genomic Medicine
33 papers in training set
Top 0.5%
1.3%
17
Stem Cell Reports
118 papers in training set
Top 0.7%
0.9%
18
Nature Communications
4913 papers in training set
Top 58%
0.9%
19
Molecular Oncology
50 papers in training set
Top 0.8%
0.8%
20
Human Molecular Genetics
130 papers in training set
Top 3%
0.8%
21
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
0.8%
22
International Journal of Epidemiology
74 papers in training set
Top 2%
0.8%
23
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
24
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
25
JAMA Network Open
127 papers in training set
Top 4%
0.8%
26
British Journal of Cancer
42 papers in training set
Top 2%
0.8%
27
PeerJ
261 papers in training set
Top 18%
0.5%
28
Cell Reports
1338 papers in training set
Top 36%
0.5%
29
Genome Medicine
154 papers in training set
Top 10%
0.5%
30
Clinical Cancer Research
58 papers in training set
Top 2%
0.5%